Notice of AGM & Posting Annual Report and Accounts

RNS Number : 2412Q

N4 Pharma PLC

25 February 2021

 

25 February 2021

N4 Pharma plc

("N4 Pharma" or the "Company")

Notice of Annual General Meeting

and

Posting of Annual Report and Accounts

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces that the Company's audited accounts for the year ended 31 December 2020, together with the notice of Annual General Meeting ("AGM"), are now available on the Company's website www.n4pharma.com and will be posted to shareholders today.

The AGM will be held at 10.00am on 24 March 2021. In line with current Covid-19 restrictions and in line with the Company's Articles of Association, this year's AGM will be a virtual meeting, full details of which are contained in the notice convening the AGM.  

Enquiries:

N4 Pharma plc
Nigel Theobald, CEO	Via IFC Advisory
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP	Tel: [phone]
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate Finance)
Vadim Alexandre/Rob Rees (Corporate Broking)
Turner Pope Investments (TPI) Limited	Tel: [phone]
Joint Broker
Andy Thacker/Zoe Alexander
IFC Advisory Ltd Financial PR Graham Herring Zach Cohen	Tel: [phone]

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.

 

END

 

 

ACSSESFILEFSESE